All In Biotech

Drug Trial Radar · NCT06349759

Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances

Randomized, Placebo-Controlled, Double-Masked Study of the Safety and Efficacy of POS (0.75% Phentolamine Ophthalmic Solution) in Subjects Who Have Previously Had Keratorefractive Surgery and Have Decreased Visual Acuity Under Mesopic Conditions

Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

200

Actual

Start

Apr 1, 2024

Primary completion

Apr 17, 2025

Study completion Feb 19, 2026

Sponsor

Lead sponsor
Opus Genetics, IncIndustry
Sponsor type
Industry
Collaborators
Viatris Inc.
First posted
Apr 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Safety and efficacy of 0.75% Phentolamine Ophthalmic Solution to improve mesopic low contrast visual acuity in subjects with post-refractive surgery visual disturbances.

Conditions

  • Mesopic Vision
  • Night Vision Loss

Interventions

  • phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonistDrug

    Once daily dosing

  • PlaceboDrug

    Once daily dosing

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects With ≥ 15 Letters (3 Lines) Improvement in mLCVA in the Study Eye at Day 15 Compared to BaselineTime frame: 15 Days

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • United States Phoenix

    Pheonix, Arizona

  • United States Scottsdale

    Scottsdale, Arizona

  • United States

    Bakersfield, California

  • United States, Glendale, CA

    Glendale, California

  • United States, LaJolla, CA

    La Jolla, California

  • United States, California

    Newport Beach, California

  • United States Rowland Heights

    Rowland Heights, California

  • United States Torrance

    Torrance, California

  • United States, Jacksonville, FL

    Jacksonville, Florida

  • United States Jacksonville

    Jacksonville, Florida

  • United States

    Tampa, Florida

  • United States Overland Park

    Overland Park, Kansas

  • United States Louisville

    Louisville, Kentucky

  • United States Fraser

    Fraser, Michigan

  • United States

    New York, New York

  • United States Smithtown

    Smithtown, New York

  • United States, North Carolina

    Garner, North Carolina

  • United States Fargo

    Fargo, North Dakota

  • United States

    Fargo, North Dakota

  • United States, Rhode Island

    Warwick, Rhode Island

  • United States, Mt Pleasant, SC

    Mt. Pleasant, South Carolina

  • United States Chattanooga

    Chattanooga, Tennessee

  • United States Smyrna

    Smyrna, Tennessee

  • United States Draper

    Draper, Utah

  • United States Lynchburg

    Lynchburg, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.